The aim of the study protocol is to measure product-specific COVID-19 vaccine effectiveness to prevent transmission of SARS-CoV-2 infection from healthcare workers to their contacts, which can be either other patients or healthcare workers, in healthcare settings.
In 2020, the European Commission stressed the importance of continuously monitoring the safety and effectiveness of vaccines in the EU/EEA during the post-authorisation phase, with particular emphasis on COVID-19 vaccines in the context of the ongoing pandemic.
The European Union Aviation Safety Agency (EASA) and the European Centre for Disease Prevention and Control (ECDC) have decided to formally retire the EASA-ECDC joint Aviation Health Safety Protocol (AHSP), while acknowledging its significant value during the high SARS-CoV-2 circulation periods during the pandemic.
ECDC and EMA have issued a joint statement on adapted COVID-19 vaccines and considerations for their use during the upcoming autumn 2023 vaccination campaigns.